Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Revenue (Most Recent Fiscal Year) | $285.14M |
Net Income (Most Recent Fiscal Year) | $-518.25M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 30.06 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.85 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -182.41% |
Net Margin (Trailing 12 Months) | -181.75% |
Return on Equity (Trailing 12 Months) | -37.19% |
Return on Assets (Trailing 12 Months) | -25.34% |
Current Ratio (Most Recent Fiscal Quarter) | 6.92 |
Quick Ratio (Most Recent Fiscal Quarter) | 6.83 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.22 |
Inventory Turnover (Trailing 12 Months) | 8.90 |
Book Value per Share (Most Recent Fiscal Quarter) | $6.88 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.40 |
Earnings per Share (Most Recent Fiscal Year) | $-1.23 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.48 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 181.91M |
Free Float | 181.88M |
Market Capitalization | $8.57B |
Average Volume (Last 20 Days) | 0.91M |
Beta (Past 60 Months) | 0.01 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.02% |
Percentage Held By Institutions (Latest 13F Reports) | 70.89% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |